The annual physical examination, in its standard form, is a remarkably blunt instrument for assessing metabolic health. A typical panel — total cholesterol, fasting glucose, basic metabolic profile — can return entirely normal results in a person who is silently developing insulin resistance, fatty liver disease, arterial inflammation, and visceral fat accumulation that will manifest as a serious cardiovascular or metabolic event a decade later.
The gap between "normal" on a standard panel and genuinely optimal metabolic health is enormous — and the biomarkers that close that gap are increasingly accessible, affordable, and actionable. Functional medicine physicians, longevity practitioners, and metabolic health specialists now routinely order a more comprehensive suite of tests that provide a far more meaningful picture of where someone's health trajectory is headed.
Here are the seven metabolic biomarkers that matter most, what optimal values look like, and what to do when results fall outside those ranges.
1. Fasting Insulin (Not Just Fasting Glucose)
Fasting glucose is the standard screening test for diabetes and prediabetes — but it is a late-stage indicator that only becomes abnormal after the pancreas has been compensating for years of insulin resistance. By the time fasting glucose rises above 100 mg/dL, significant metabolic damage has typically already occurred.
Fasting insulin is the early-warning system. As insulin resistance develops, the pancreas produces increasingly more insulin to maintain normal glucose levels. Fasting insulin rises — sometimes to 3–5 times optimal levels — while glucose remains perfectly normal on standard tests.
Optimal range: 2–6 µIU/mL fasting. Values of 10–15 µIU/mL indicate significant insulin resistance despite normal glucose. Values above 20 µIU/mL represent advanced insulin resistance.
HOMA-IR calculation: (Fasting insulin × Fasting glucose) ÷ 405. A HOMA-IR below 1.0 is optimal; above 2.0 confirms insulin resistance.
What to do: Fasting insulin responds rapidly to dietary change — reducing refined carbohydrates, implementing time-restricted eating, and increasing physical activity can normalize fasting insulin within 4–8 weeks. Retest at 3-month intervals during intervention.
2. HbA1c (Glycated Hemoglobin) — With Context
HbA1c measures the percentage of hemoglobin molecules with glucose attached — effectively averaging blood sugar exposure over the preceding 2–3 months. It is the standard long-term glycemic control marker for diabetics, but its utility as a screening tool is increasingly recognized for non-diabetic adults.
Standard clinical ranges: Below 5.7% normal; 5.7–6.4% prediabetes; 6.5%+ diabetes.
Optimal longevity range: Longevity practitioners (Attia, Rhonda Patrick, Mark Hyman) typically target 5.0–5.4% as the sweet spot associated with minimal glycation-related tissue damage and lowest cardiovascular risk — a meaningfully lower target than the clinical "normal" ceiling of 5.7%.
Important caveat: HbA1c can be falsely low in people with high red blood cell turnover (iron deficiency anemia, hemolytic conditions) and falsely high in those with low turnover. Fasting glucose and fasting insulin together provide more accurate metabolic assessment when HbA1c reliability is in question.
3. Triglyceride-to-HDL Ratio
The triglyceride-to-HDL ratio is arguably the most powerful single cardiovascular and metabolic risk biomarker available from a standard lipid panel — yet it is rarely calculated or communicated to patients.
High triglycerides reflect excess carbohydrate intake, insulin resistance, and elevated hepatic de novo lipogenesis. Low HDL reflects the same metabolic dysfunction. The ratio captures both simultaneously and is a strong surrogate marker for small, dense LDL particles (pattern B LDL) — the most atherogenic LDL phenotype — which standard total LDL measurements cannot distinguish.
Optimal ratio: Below 1.5 (using mg/dL units) or below 0.87 (mmol/L). A ratio above 3.0 is considered high risk and strongly suggests significant insulin resistance and atherogenic dyslipidemia.
What to do: This ratio responds dramatically to carbohydrate reduction (particularly refined carbohydrates and added sugar), increased omega-3 fatty acid intake, Zone 2 exercise, and weight loss. It is one of the fastest-improving biomarkers in response to dietary intervention — often showing meaningful changes within 4–6 weeks.
4. hsCRP (High-Sensitivity C-Reactive Protein)
C-reactive protein is an acute-phase inflammatory protein produced by the liver. The high-sensitivity assay (hsCRP) detects low-level chronic inflammation at concentrations below the threshold of standard CRP tests — making it a cardiovascular and metabolic risk marker of significant predictive value.
Chronic low-grade inflammation — driven by visceral adiposity, dysbiosis, insulin resistance, oxidative stress, and ultra-processed diet — is the mechanistic foundation of atherosclerosis, metabolic syndrome, neurodegenerative disease, and several cancers. hsCRP is its most accessible surrogate measure.
Optimal: Below 0.5 mg/L. 0.5–1.0 mg/L is good. 1.0–3.0 mg/L is moderate risk. Above 3.0 mg/L represents elevated inflammatory state requiring intervention.
What to do: hsCRP responds to omega-3 supplementation (2–3g EPA+DHA daily), Mediterranean dietary pattern, regular exercise, weight loss, sleep improvement, and stress reduction — the same interventions that address the upstream drivers of chronic inflammation. Acute infections can transiently raise hsCRP dramatically; always retest after any illness resolves.
5. ApoB (Apolipoprotein B)
ApoB is the structural protein present on every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Because each of these particles carries exactly one ApoB molecule, the ApoB concentration directly reflects the total number of atherogenic particles in the blood — a more meaningful cardiovascular risk indicator than total LDL cholesterol, which measures the cholesterol mass within these particles rather than the particle count.
A person can have a normal total LDL but an elevated ApoB if they have many small, dense LDL particles (each carrying less cholesterol but more individually atherogenic). This pattern — common in insulin-resistant individuals on high-carbohydrate diets — is entirely missed by standard LDL measurement.
Optimal: Below 80 mg/dL for people without cardiovascular risk factors; below 60–70 mg/dL for high-risk individuals or those with established cardiovascular disease.
What to do: ApoB is reduced by statins (the most powerful pharmaceutical intervention), reduced saturated fat intake, improved insulin sensitivity, and weight loss. It is also significantly elevated by high fructose intake through increased hepatic VLDL production — another reason to prioritize fructose reduction in metabolic health optimization.
6. Vitamin D (25-OH Vitamin D)
Vitamin D has transitioned from a bone health nutrient to a recognized broad-spectrum immune modulator, hormonal regulator, and cardiovascular protective compound. Its receptor (VDR) is present in virtually every cell type in the body, reflecting its system-wide regulatory roles.
Deficiency (below 20 ng/mL) is associated with increased risk of autoimmune conditions, depression, cardiovascular disease, several cancers, insulin resistance, and impaired immune response. An estimated 40–50% of adults in developed countries are deficient.
Optimal range: 40–60 ng/mL (100–150 nmol/L). This range is consistently associated with the lowest risk of the conditions linked to deficiency — significantly above the clinical deficiency threshold of 20 ng/mL, which merely prevents rickets.
Supplementation: Most adults require 2,000–4,000 IU vitamin D3 daily with a fat-containing meal to achieve optimal levels. Darker skin pigmentation, higher body weight, limited sun exposure, and older age all increase requirements. Retest after 3 months of supplementation to confirm target range achievement.
7. Uric Acid
Uric acid is the end product of purine metabolism, primarily from fructose catabolism and cellular DNA turnover. Long associated solely with gout, uric acid has emerged as a significant independent predictor of metabolic syndrome, insulin resistance, cardiovascular disease, kidney disease, and non-alcoholic fatty liver disease.
High fructose intake — from sugar-sweetened beverages, processed foods, and excess fruit juice — rapidly raises uric acid through a unique pathway: fructose metabolism in the liver and intestine is the primary dietary driver of uric acid production, which is why uric acid elevation tracks closely with the same dietary patterns that drive MASLD and insulin resistance.
Optimal: Below 5.5 mg/dL (below 327 µmol/L) for metabolic health optimization. The clinical gout threshold of 6.8–7.0 mg/dL dramatically understates the metabolic risk of chronically elevated uric acid.
What to do: Eliminating sugar-sweetened beverages and reducing fructose-containing foods produces the fastest uric acid reduction. Adequate hydration, cherry juice (tart cherry specifically), and vitamin C supplementation also support uric acid clearance. Low-purine diets (reducing organ meats, shellfish) are less impactful than fructose reduction for most people.
Building Your Metabolic Health Monitoring Routine
A practical protocol for comprehensive metabolic monitoring:
Baseline testing (annually or biannually): Fasting insulin + fasting glucose (calculate HOMA-IR), HbA1c, full lipid panel with triglyceride-to-HDL ratio calculation, ApoB, hsCRP, vitamin D (25-OH), uric acid.
Cost: Most of these tests are available through standard blood panels at major laboratories at modest cost. Fasting insulin is the most commonly omitted — specifically request it. ApoB may require a specific physician request or direct-to-consumer lab service.
Intervention monitoring: After initiating dietary or lifestyle changes, retest the specific abnormal markers at 3-month intervals to assess response and guide adjustment.
The Bottom Line
These seven biomarkers — fasting insulin, HbA1c, triglyceride-to-HDL ratio, hsCRP, ApoB, vitamin D, and uric acid — provide a metabolic health picture that standard annual checkups cannot match. Most are available through routine labs, cost relatively little, and respond measurably to dietary and lifestyle interventions. Testing them is not premature concern — it is the earliest possible opportunity to act, while the window for dietary and lifestyle reversal is widest.
